Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study

Overview of attention for article published in Cancer Cell International, July 2004

Altmetric Badge

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 1 Dimensions

Summary Patents Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

Expression of EpCAM in uveal melanoma

Article in Cancer Cell International (November 2006)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.